Social media may be a potential minefield for Big Pharma, but some companies are finding their way safely. One of them is Sanofi ($SNY), which recovered from a Facebook slap from a disgruntled patient to move into the online networking world in a big way, at least when it comes to diabetes. The French drugmaker, like several of its rivals, is counting on growth in the diabetes market to help fuel its own sales. One way Sanofi is trying to set itself apart from other makers of diabetes medications is by engaging with patients online. Article